Novavax Stock Forecast, Price & News

Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

What stocks does MarketBeat like better than Novavax?

Wall Street analysts have given Novavax a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novavax wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novavax?

Novavax saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 7,180,000 shares, an increase of 21.9% from the July 29th total of 5,890,000 shares. Based on an average trading volume of 4,960,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 9.8% of the company's shares are sold short.
View Novavax's Short Interest.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Novavax.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) posted its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($4.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($3.63) by $1.12. The biopharmaceutical company earned $298.02 million during the quarter, compared to analyst estimates of $370.80 million. Novavax had a negative net margin of 80.37% and a negative trailing twelve-month return on equity of 150.88%. During the same period last year, the company posted ($0.30) earnings per share.
View Novavax's earnings history.

How has Novavax's stock been impacted by COVID-19?

Novavax's stock was trading at $10.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVAX stock has increased by 2,261.2% and is now trading at $248.16.
View which stocks have been most impacted by COVID-19.

When did Novavax's stock split? How did Novavax's stock split work?

Novavax's stock reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

6 analysts have issued 1-year price targets for Novavax's stock. Their forecasts range from $161.00 to $294.00. On average, they anticipate Novavax's share price to reach $249.60 in the next twelve months. This suggests a possible upside of 0.6% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?

Novavax's management team includes the following people:

• Stanley C. Erck, President, Chief Executive Officer & Director
• Richard Crowley, Chief Operating Officer & Executive Vice President
• James Patrick Kelly, Chief Financial Officer, Treasurer & Executive VP
• Gregory M. Glenn, President-Research & Development (LinkedIn Profile)
• Filip Dubovsky, Chief Medical Officer & Executive Vice President

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Who are some of Novavax's key competitors?

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Repligen (RGEN), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NVAX's competitors.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.96%), RA Capital Management L.P. (3.44%), State Street Corp (2.27%), Susquehanna International Group LLP (0.00%), Citadel Advisors LLC (0.00%) and Franklin Resources Inc. (1.48%). Company insiders that own Novavax stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax.

Which major investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., RA Capital Management L.P., Price T Rowe Associates Inc. MD, Northern Trust Corp, IMC Chicago LLC, Geode Capital Management LLC, Franklin Resources Inc., and Creative Planning. Company insiders that have sold Novavax company stock in the last year include David M Mott, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax or view top insider-selling stocks.

Which major investors are buying Novavax stock?

NVAX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Simplex Trading LLC, PEAK6 Investments LLC, State Street Corp, Sumitomo Mitsui Trust Holdings Inc., Legal & General Group Plc, Swiss National Bank, and Ikarian Capital LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $248.16.

How much money does Novavax make?

Novavax has a market capitalization of $18.48 billion and generates $475.60 million in revenue each year. The biopharmaceutical company earns $-418,260,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 791 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

Where are Novavax's headquarters?

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at (240) 268-2000 or via email at [email protected].